In the past week, ROIV stock has gone down by -2.04%, with a monthly gain of 16.91% and a quarterly surge of 2.03%. The volatility ratio for the week is 3.20%, and the volatility levels for the last 30 days are 4.14% for Roivant Sciences Ltd The simple moving average for the last 20 days is 4.39% for ROIV stock, with a simple moving average of -1.75% for the last 200 days.
Is It Worth Investing in Roivant Sciences Ltd (NASDAQ: ROIV) Right Now?
The 36-month beta value for ROIV is at 1.23. Analysts have varying views on the stock, with 6 analysts rating it as a “buy,” 3 rating it as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for ROIV is 438.55M, and currently, shorts hold a 11.68% of that float. The average trading volume for ROIV on May 07, 2025 was 6.61M shares.
ROIV) stock’s latest price update
Roivant Sciences Ltd (NASDAQ: ROIV)’s stock price has decreased by -4.41 compared to its previous closing price of 11.57. However, the company has seen a -2.04% decrease in its stock price over the last five trading sessions. seekingalpha.com reported 2025-04-23 that Roivant Sciences has strengthened its financial position through strategic divestitures, boasting $5.2 billion in cash and assets, enabling robust funding for its late-stage pipeline. The company’s FcRn inhibitor platform, led by IMVT-1402, shows promise in autoimmune diseases, with positive clinical readouts validating its potential. Priovant’s brepocitinib, targeting TYK2/JAK1 pathways, is advancing in Phase 3 trials for Dermatomyositis and Non-Infectious Uveitis, addressing significant unmet needs.
Analysts’ Opinion of ROIV
Many brokerage firms have already submitted their reports for ROIV stocks, with Wolfe Research repeating the rating for ROIV by listing it as a “Outperform.” The predicted price for ROIV in the upcoming period, according to Wolfe Research is $17 based on the research report published on February 15, 2024 of the previous year 2024.
Piper Sandler, on the other hand, stated in their research note that they expect to see ROIV reach a price target of $20. The rating they have provided for ROIV stocks is “Overweight” according to the report published on January 05th, 2024.
Deutsche Bank gave a rating of “Buy” to ROIV, setting the target price at $14 in the report published on December 12th of the previous year.
ROIV Trading at 5.30% from the 50-Day Moving Average
After a stumble in the market that brought ROIV to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -15.28% of loss for the given period.
Volatility was left at 4.14%, however, over the last 30 days, the volatility rate increased by 3.20%, as shares surge +19.44% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +5.13% upper at present.
During the last 5 trading sessions, ROIV fell by -2.04%, which changed the moving average for the period of 200-days by -0.45% in comparison to the 20-day moving average, which settled at $10.60. In addition, Roivant Sciences Ltd saw -6.51% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ROIV starting from Ramaswamy Vivek, who proposed sale 273,959 shares at the price of $11.47 back on May 06 ’25. After this action, Ramaswamy Vivek now owns shares of Roivant Sciences Ltd, valued at $3,143,287 using the latest closing price.
Venker Eric, the President & COO of Roivant Sciences Ltd, sale 100,000 shares at $10.22 during a trade that took place back on Apr 21 ’25, which means that Venker Eric is holding 1,116,345 shares at $1,022,000 based on the most recent closing price.
Stock Fundamentals for ROIV
Current profitability levels for the company are sitting at:
- -10.27 for the present operating margin
- 0.89 for the gross margin
The net margin for Roivant Sciences Ltd stands at -1.2. The total capital return value is set at -0.18. Equity return is now at value -7.10, with -6.11 for asset returns.
Based on Roivant Sciences Ltd (ROIV), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -7.73. The debt to equity ratio resting at 0.02. The interest coverage ratio of the stock is -48.72.
Currently, EBITDA for the company is 4.31 billion with net debt to EBITDA at -0.43. When we switch over and look at the enterprise to sales, we see a ratio of 61.52. The liquidity ratio also appears to be rather interesting for investors as it stands at 37.91.
Conclusion
In conclusion, Roivant Sciences Ltd (ROIV) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
